- Can you have too many relationships with introducers? (part 1)
- How To Integrate Continuous Improvement Into Your Organization’s Culture And Daily Activities
- Identify The Strengths Of Your Services And Where Improvements Can Be Leveraged
- How To Succeed In A Continually Changing And Unstructured Workplace
- 6 tips to get back in touch with an old colleague
- Paving the Last Mile of Big Data Analytics
- Important Considerations For An Organizational Restructuring
- Elevator Speech 2.0 = Elevator Dialogue
- 4 ways to qualify a lead
- Is the Trusted Advisor Still Trusted?
Deloitte: Global life sciences outlook
December 21, 2012
By Rob Starr, Content Manager, Big4.com
In an effort to deliver better patient outcomes while at the same time counter slow market growth and declining profitability, the global healthcare industry has adopted a new business model that shifts its focus from developing blockbuster drugs and building pipelines to business portfolio evolution, the regulatory landscape and emerging markets and treatment changes outcomes, according to a new report by Deloitte Touche Tohmatsu Limited (DTTL).
The report, 2013 global life sciences outlook: Optimism tempered by reality in a “new normal”, also closely examines the current state of the global life sciences industry and the top issues facing stakeholders. It provides a snapshot of activity in a number of geographic markets such as health care reforms, cost controls, government industry incentives and economic impacts on the industry, along with considerations companies may adopt to grow revenue and market share in 2013 and beyond.
John Rhodes, Life Sciences Sector Leader, DTTL comments:
“To grow in this challenging climate, the global life sciences industry is transitioning away from a primary-care, small-molecule-driven sales model towards targeting specialist secondary care indications through the use of high-value biologic therapies in the developed markets, while also taking a global perspective by marketing branded and off-patent medicines in the fast-growing emerging markets,” he says.